LTRN — Lantern Pharma Balance Sheet
0.000.00%
- $38.18m
- $14.16m
- 18
- 19
- 33
- 12
Annual balance sheet for Lantern Pharma, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 19.2 | 70.7 | 55.2 | 41.3 | 24 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 20.2 | 72.7 | 58.7 | 43.3 | 25.2 |
Net Property, Plant And Equipment | 0.022 | 0.216 | 0.096 | 0.28 | 0.287 |
Other Long Term Assets | |||||
Total Assets | 20.4 | 74 | 58.8 | 43.6 | 25.6 |
Payable / Accrued | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Total Current Liabilities | 0.552 | 2.33 | 2.8 | 2.68 | 4.33 |
Long Term Debt | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 0.661 | 2.38 | 2.8 | 2.74 | 4.38 |
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Other Equity | |||||
Total Equity | 19.7 | 71.6 | 56 | 40.9 | 21.2 |
Total Liabilities & Shareholders' Equity | 20.4 | 74 | 58.8 | 43.6 | 25.6 |
Total Common Shares Outstanding |